Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure

Cardiovascular Revascularization Medicine - Tập 7 - Trang 234-236 - 2006
Andrew E. Ajani1,2, Thomas H. Marwick3, Henry Krum2
1Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia
2National Health Medical Research Council, Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
3University of Queensland Department of Medicine, Princess Alexandra Hospital, Brisbane, Australia

Tài liệu tham khảo

Steg, 2004, Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE), Circulation, 109, 494, 10.1161/01.CIR.0000109691.16944.DA

Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001

Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207

Pitt, 2005, Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure, J Am Coll Cardiol, 46, 425, 10.1016/j.jacc.2005.04.038

Borghi, 1999, Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of myocardial infarction long-term evaluation, Am J Hypertens, 12, 665, 10.1016/S0895-7061(99)00042-4

Solomon, 2005, Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both, N Engl J Med, 352, 2581, 10.1056/NEJMoa043938

Cannon, 2001, Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban, N Engl J Med, 344, 1879, 10.1056/NEJM200106213442501

Wallentin, 2000, Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Fast revascularisation during instability in coronary artery disease, Lancet, 356, 9, 10.1016/S0140-6736(00)02427-2

Juurlink, 2004, Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study, N Engl J Med, 351, 543, 10.1056/NEJMoa040135